优宁维(301166)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301166 优宁维

已收盘 01-09 15:00:00

{"stockData":{"symbol":"301166","market":"SZ","secType":"STK","nameCN":"优宁维","latestPrice":31.35,"timestamp":1767942237000,"preClose":31,"halted":0,"volume":1189400,"delay":0,"changeRate":0.0113,"floatShares":56918700,"shares":86666700,"eps":-0.2194,"marketStatus":"已收盘","change":0.35,"latestTime":"01-09 15:00:00","open":31.01,"high":31.35,"low":30.84,"amount":37030200,"amplitude":0.0165,"askPrice":31.38,"askSize":38,"bidPrice":31.35,"bidSize":218,"shortable":0,"etf":0,"ttmEps":-0.2194,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768181400000},"marketStatusCode":5,"adr":0,"adjPreClose":31,"symbolType":"stock","openAndCloseTimeList":[[1767922200000,1767929400000],[1767934800000,1767942000000]],"highLimit":34.1,"lowLimit":27.9,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":86666668,"isCdr":false,"pbRate":1.33,"roa":"--","roe":"--","epsLYR":0.12,"committee":0.63145,"marketValue":2717000000,"turnoverRate":0.0209,"status":0,"floatMarketCap":1784000000},"requestUrl":"/m/hq/s/301166","defaultTab":"news","newsList":[{"id":"2601383788","title":"股市必读：优宁维（301166）1月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601383788","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601383788?lang=zh_cn&edition=full","pubTime":"2026-01-08 02:51","pubTimestamp":1767811868,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，优宁维报收于30.79元，上涨0.03%，换手率1.85%，成交量1.06万手，成交额3246.84万元。董秘最新回复投资者： 冷总，您好，请问公司在脑机接口领域布局了哪些？当日关注点来自交易信息汇总：1月7日主力资金净流入154.9万元，显示主力对优宁维短期走势持积极态度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800001360.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2601582303","title":"优宁维：公司参与投资的股权投资基金投向覆盖医疗健康等领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2601582303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601582303?lang=zh_cn&edition=full","pubTime":"2026-01-07 11:33","pubTimestamp":1767756792,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)01月06日在投资者关系平台上答复投资者关心的问题。投资者提问：祁总，公司参股的创投基金有没有参与脑机接口？优宁维回复：投资者您好，公司参与投资的股权投资基金投向覆盖医疗健康等领域，投资者可关注相关基金的投资进展。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700013718.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159760","BK0250","301166"],"gpt_icon":0},{"id":"2601000794","title":"优宁维（301166）披露关于回购公司股份的进展公告，1月5日股价上涨3.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601000794","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601000794?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:33","pubTimestamp":1767609203,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，优宁维报收于30.66元，较前一交易日上涨3.3%，最新总市值为26.57亿元。该股当日开盘29.89元，最高30.68元，最低29.68元，成交额达4881.69万元，换手率为2.82%。公司近日发布公告，就回购公司股份的进展情况作出说明。根据公告，上海优宁维生物科技股份有限公司于2025年4月10日召开董事会及监事会会议，于2025年5月13日召开股东大会，审议通过回购公司股份方案。本次回购符合相关规定，公司后续将继续实施回购计划并履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500029227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2601200657","title":"优宁维：建立现代化仓储物流配送系统","url":"https://stock-news.laohu8.com/highlight/detail?id=2601200657","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601200657?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:45","pubTimestamp":1767599118,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维01月04日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500015797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2601006804","title":"优宁维：借助大数据完善客户画像","url":"https://stock-news.laohu8.com/highlight/detail?id=2601006804","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601006804?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:45","pubTimestamp":1767599117,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维01月04日在投资者关系平台上答复投资者关心的问题。作为实现一站式服务的重要支撑，公司不断迭代升级在线商城，上线UCRM、CRM、实验室管理系统、OA、OMS等系统，助力公司业务和管理效率提升，并积极借助大数据等技术，基于公司积累的客户数据，完善客户画像，以更加精准地为客户提供相关产品和服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500015794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166","159739"],"gpt_icon":0},{"id":"2600601640","title":"每周股票复盘：优宁维（301166）部分募投项目结项并补流235.01万","url":"https://stock-news.laohu8.com/highlight/detail?id=2600601640","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600601640?lang=zh_cn&edition=full","pubTime":"2026-01-03 03:50","pubTimestamp":1767383420,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，优宁维报收于29.68元，较上周的29.75元下跌0.24%。本周，优宁维12月29日盘中最高价报30.02元。优宁维当前最新总市值25.72亿元，在生物制品板块市值排名48/51，在两市A股市值排名4820/5181。本周关注点公司公告汇总：优宁维同意将两个募投项目结项，节余募集资金235.01万元永久补充流动资金。公司公告汇总：优宁维将“线上营销网络与信息化建设项目”和“蛋白及抗体试剂研发技改项目”延期至2026年12月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300002370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2595778553","title":"优宁维（301166）披露部分募投项目延期公告，12月31日股价下跌0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595778553","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595778553?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:58","pubTimestamp":1767175119,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，优宁维报收于29.68元，较前一交易日下跌0.07%，最新总市值为25.72亿元。该股当日开盘29.9元，最高29.9元，最低29.44元，成交额达2417.49万元，换手率为1.43%。近日，上海优宁维生物科技股份有限公司发布公告称，公司于2025年12月30日召开第四届董事会第十次会议，审议通过部分募投项目延期的议案。本次延期未改变项目实施主体、方式、投资规模及募集资金用途，不影响公司正常经营，不存在变相改变募集资金投向的情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100033191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2595635687","title":"优宁维：期待为辉瑞及默沙东提供服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2595635687","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595635687?lang=zh_cn&edition=full","pubTime":"2025-12-30 11:34","pubTimestamp":1767065679,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)12月30日在投资者关系平台上答复投资者关心的问题。投资者提问：祁总，公司说海外市场是公司要大力拓展的业务，公司有没有和辉瑞制药或者默沙东有合作呢？优宁维回复：投资者您好，公司客户主要为国内高等院校、科研院所、医院和生物医药企业等。随着公司自主品牌产品持续丰富、海外市场的持续拓展，公司期待为包括辉瑞制药及默沙东在内的生物医药头部企业提供相关产品和服务。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000016159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2595763811","title":"优宁维：借助大数据完善客户画像","url":"https://stock-news.laohu8.com/highlight/detail?id=2595763811","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595763811?lang=zh_cn&edition=full","pubTime":"2025-12-30 11:34","pubTimestamp":1767065678,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维12月30日在投资者关系平台上答复投资者关心的问题。作为实现一站式服务的重要支撑，公司不断迭代升级在线商城，上线UCRM、CRM、实验室管理系统、OA、OMS等系统，助力公司业务和管理效率提升，并积极借助大数据等技术，基于公司积累的客户数据，完善客户画像，以更加精准地客户提供相关产品和服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000016153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","159739","BK0250"],"gpt_icon":0},{"id":"2594291994","title":"优宁维：针对海外市场，目前主要通过海外电商平台、参加海外展会等方式进行市场拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2594291994","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594291994?lang=zh_cn&edition=full","pubTime":"2025-12-26 21:38","pubTimestamp":1766756280,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：董秘你好，公司在医药电商领域有布局宣传销售公司产品吗？优宁维（301166.SZ）12月26日在投资者互动平台表示，公司目前形成了线上+线下双渠道销售模式，线上渠道方面，主要通过自有商城、微信、抖音等平台以及第三方专业服务网站展示、销售公司产品，提升公司产品曝光度；此外针对海外市场，目前主要通过海外电商平台、参加海外展会等方式进行市场拓展。（文章来源：每日经济新闻）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-26/doc-inhecwez7848519.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-26/doc-inhecwez7848519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2594028352","title":"优宁维：已在海口等全国设18个办事处及11个子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2594028352","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594028352?lang=zh_cn&edition=full","pubTime":"2025-12-25 08:33","pubTimestamp":1766622784,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)12月24日在投资者关系平台上答复投资者关心的问题。投资者提问：祁总，公司有在海南设立子公司吗？优宁维回复：投资者您好。公司作为全国布局的生命科学一站式服务商，已在海口等全国各地设有18个办事处及11个子公司。未来公司将会根据业务开展情况，综合考虑优化业务布局，借助相关地区的政策优势加快业务发展。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500004853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2594340403","title":"股市必读：优宁维（301166）12月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2594340403","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594340403?lang=zh_cn&edition=full","pubTime":"2025-12-25 05:05","pubTimestamp":1766610317,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘，优宁维报收于29.97元，上涨0.6%，换手率1.01%，成交量5744.0手，成交额1713.07万元。董秘最新回复投资者： 冷总，您好！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500002033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2593073424","title":"优宁维：公司产品可应用于生命科学各研究领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2593073424","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593073424?lang=zh_cn&edition=full","pubTime":"2025-12-24 15:07","pubTimestamp":1766560042,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)12月24日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好公司有涉足辅助生殖领域吗？公司是否有用机器人来提高生产效率？优宁维回复：投资者您好，公司主要面向国内高等院校、科研院所、医院和生物医药企业等科研端，提供生命科学试剂、设备、耗材、综合技术服务等产品和服务，理论上公司产品可以应用于生命科学各个研究领域。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400019107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2593424032","title":"优宁维：2025年上半年自主品牌业务实现20%以上增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2593424032","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593424032?lang=zh_cn&edition=full","pubTime":"2025-12-24 15:07","pubTimestamp":1766560041,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维12月24日在投资者关系平台上答复投资者关心的问题。公司围绕抗体，持续加强投入，并依托现有销售资源，自主品牌业务拓展加速进行，2025年上半年自主品牌业务实现20%以上增长，自主品牌业务收入占比进一步提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400019105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2593422894","title":"优宁维：创新药研发是公司产品主要应用领域之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2593422894","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593422894?lang=zh_cn&edition=full","pubTime":"2025-12-24 15:05","pubTimestamp":1766559928,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)12月24日在投资者关系平台上答复投资者关心的问题。投资者提问：祁总，公司有没有向创新药或者脑机接口进军布局？优宁维回复：投资者您好，公司主要面向国内高等院校、科研院所、医院和生物医药企业等科研端，提供生命科学试剂、设备、耗材、综合技术服务等产品和服务。创新药研发是公司产品的主要应用领域之一。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400019045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0250","159992","301166","BK1574","06978"],"gpt_icon":0},{"id":"2592419805","title":"优宁维（301166）披露使用闲置募集资金及自有资金进行现金管理的进展公告，12月19日股价上涨0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592419805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592419805?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:45","pubTimestamp":1766155552,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘，优宁维报收于30.05元，较前一交易日上涨0.5%，最新总市值为26.04亿元。公司近日发布公告，披露了关于使用闲置募集资金及自有资金进行现金管理的进展。公告显示，上海优宁维生物科技股份有限公司近期使用闲置募集资金及自有资金购买了多笔结构性存款产品，涉及浦发银行、兴业银行、交通银行等金融机构。截至目前，未到期的现金管理余额中，募集资金为5,400万元，自有资金为77,300万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900039968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2592152193","title":"优宁维：提供生命科学试剂设备耗材等产品服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2592152193","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592152193?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:54","pubTimestamp":1766134468,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)12月19日在投资者关系平台上答复投资者关心的问题。投资者提问：冷总，公司是医药商业还是医药电商？优宁维回复：投资者您好，公司主要面向国内高等院校、科研院所、医院和生物医药企业等科研端，提供生命科学试剂、设备、耗材、综合技术服务等产品和服务。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900024868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2592454942","title":"优宁维：2025年上半年自主品牌业务实现20%以上增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2592454942","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592454942?lang=zh_cn&edition=full","pubTime":"2025-12-18 08:36","pubTimestamp":1766018168,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维12月17日在投资者关系平台上答复投资者关心的问题。经过多年持续投入，公司在“抗体极致”战略引领下，自主品牌业务拓展加速进行，2025年上半年公司自主品牌业务实现20%以上增长，自主品牌收入占比进一步提升；自主品牌产品持续丰富，截至2025年上半年末，公司杭州抗体研发中心累计研发产品SPU数超4,200个，南京蛋白研发中心累计研发产品SPU数超1,800个，公司自主品牌产品进一步丰富。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800004505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2590399329","title":"优宁维：围绕抗体上下游寻找并购标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2590399329","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590399329?lang=zh_cn&edition=full","pubTime":"2025-12-09 11:36","pubTimestamp":1765251404,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)12月08日在投资者关系平台上答复投资者关心的问题。投资者提问：冷总，您好公司超募这么多资金，证监会鼓励并购重组加快转型，公司怎么还没落实？优宁维回复：投资者您好， 公司围绕一站式平台极致战略和抗体极致战略，致力于通过围绕抗体上下游应用领域寻找相关标的企业，以实现与现有业务的协同发展。公司将严格遵守信息披露相关规定，如有需要披露的实质性进展或达到披露标准的交易，将及时发布公告。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900013578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2588407660","title":"优宁维：公司2025年开展了9次投资者调研","url":"https://stock-news.laohu8.com/highlight/detail?id=2588407660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588407660?lang=zh_cn&edition=full","pubTime":"2025-12-04 09:15","pubTimestamp":1764810910,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)12月03日在投资者关系平台上答复投资者关心的问题。投资者提问：冷总，公司基本上没有机构去调研，也没有券商写研究报告，这就是咱们公司在资本市场的形象，还是董秘工作需要加强改善！优宁维回复：投资者您好，公司2025年开展了9次投资者调研及2次投资者集体接待日活动，具体情况您可关注互动易平台披露的调研记录。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400005333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767947561841,"stockEarnings":[{"period":"1week","weight":0.0445},{"period":"1month","weight":0.0151},{"period":"3month","weight":0.0026},{"period":"6month","weight":-0.0184},{"period":"1year","weight":0.1476},{"period":"ytd","weight":0.0445}],"compareEarnings":[{"period":"1week","weight":0.0288},{"period":"1month","weight":0.0444},{"period":"3month","weight":0.0477},{"period":"6month","weight":0.1632},{"period":"1year","weight":0.264},{"period":"ytd","weight":0.0288}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海优宁维生物科技股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"9893人(较上一季度减少13.19%)","perCapita":"5753股","listingDate":"2021-12-28","address":"上海市杨浦区控江路1690号1505室","registeredCapital":"8666万元","survey":"　　上海优宁维生物科技股份有限公司的主营业务是提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。公司的主要产品是生命科学试剂、生命科学仪器及耗材、综合技术服务。","listedPrice":86.06},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"优宁维(301166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供优宁维(301166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"优宁维,301166,优宁维股票,优宁维股票老虎,优宁维股票老虎国际,优宁维行情,优宁维股票行情,优宁维股价,优宁维股市,优宁维股票价格,优宁维股票交易,优宁维股票购买,优宁维股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"优宁维(301166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供优宁维(301166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}